Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Contemporary tetracycline susceptibility testing: doxycycline MIC methods and interpretive criteria (CLSI and EUCAST) performance when testing Gram-positive pathogens.

Jones RN, Stilwell MG, Wilson ML, Mendes RE.

Diagn Microbiol Infect Dis. 2013 May;76(1):69-72. doi: 10.1016/j.diagmicrobio.2013.01.023. Epub 2013 Mar 13.

PMID:
23490012
2.

Contemporary potencies of minocycline and tetracycline HCL tested against Gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria.

Jones RN, Wilson ML, Weinstein MP, Stilwell MG, Mendes RE.

Diagn Microbiol Infect Dis. 2013 Apr;75(4):402-5. doi: 10.1016/j.diagmicrobio.2013.01.022.

PMID:
23514756
3.

Development of doxycycline MIC and disk diffusion interpretive breakpoints and revision of tetracycline breakpoints for Streptococcus pneumoniae.

Dallas SD, McGee L, Limbago B, Patel JB, McElmeel ML, Fulcher LC, Lonsway DR, Jorgensen JH.

J Clin Microbiol. 2013 Jun;51(6):1798-802. doi: 10.1128/JCM.00125-13. Epub 2013 Apr 3.

4.

Pharmacodynamics of doxycycline and tetracycline against Staphylococcus pseudintermedius: proposal of canine-specific breakpoints for doxycycline.

Maaland MG, Papich MG, Turnidge J, Guardabassi L.

J Clin Microbiol. 2013 Nov;51(11):3547-54. doi: 10.1128/JCM.01498-13. Epub 2013 Aug 21.

5.

Evaluation of canine-specific minocycline and doxycycline susceptibility breakpoints for meticillin-resistant Staphylococcus pseudintermedius isolates from dogs.

Hnot ML, Cole LK, Lorch G, Papich MG, Rajala-Schultz PJ, Daniels JB.

Vet Dermatol. 2015 Oct;26(5):334-8, e70-1. doi: 10.1111/vde.12227. Epub 2015 Jul 28.

PMID:
26216025
6.

Reevaluation of Clinical and Laboratory Standards Institute disk diffusion breakpoints for tetracyclines for testing Enterobacteriaceae.

Sader HS, Ferraro MJ, Reller LB, Schreckenberger PC, Swenson JM, Jones RN.

J Clin Microbiol. 2007 May;45(5):1640-3. Epub 2007 Mar 14.

7.

Validation of EUCAST zone diameter breakpoints against reference broth microdilution.

Bengtsson S, Bjelkenbrant C, Kahlmeter G.

Clin Microbiol Infect. 2014 Jun;20(6):O353-60. doi: 10.1111/1469-0691.12414. Epub 2013 Nov 13.

8.
9.

Clinical breakpoint changes and their impact on surveillance of antimicrobial resistance in Escherichia coli causing bacteraemia.

van der Bij AK, van Dijk K, Muilwijk J, Thijsen SF, Notermans DW, de Greeff S, van de Sande-Bruinsma N; ISIS-AR study group.

Clin Microbiol Infect. 2012 Nov;18(11):E466-72. doi: 10.1111/j.1469-0691.2012.03996.x. Epub 2012 Aug 27.

10.

Comparison of antimicrobial pharmacokinetic/pharmacodynamic breakpoints with EUCAST and CLSI clinical breakpoints for Gram-positive bacteria.

Asín E, Isla A, Canut A, Rodríguez Gascón A.

Int J Antimicrob Agents. 2012 Oct;40(4):313-22. doi: 10.1016/j.ijantimicag.2012.06.005. Epub 2012 Aug 22.

PMID:
22921422
11.

Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.

Biedenbach DJ, Farrell DJ, Flamm RK, Liverman LC, McIntyre G, Jones RN.

Int J Antimicrob Agents. 2012 Apr;39(4):321-5. doi: 10.1016/j.ijantimicag.2011.11.016. Epub 2012 Feb 4.

PMID:
22306239
12.

Development of interpretive criteria and quality control limits for macrolide and clindamycin susceptibility testing of Streptococcus pneumoniae.

Jorgensen JH, Swenson JM, Tenover FC, Barry A, Ferraro MJ, Murray PR, Reller LB.

J Clin Microbiol. 1996 Nov;34(11):2679-84.

13.

Evaluation of minocycline susceptibility of methicillin-resistant Staphylococcus pseudintermedius.

Weese JS, Sweetman K, Edson H, Rousseau J.

Vet Microbiol. 2013 Mar 23;162(2-4):968-71. doi: 10.1016/j.vetmic.2012.10.002. Epub 2012 Oct 11.

PMID:
23107659
14.

Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli.

Hombach M, Bloemberg GV, Böttger EC.

J Antimicrob Chemother. 2012 Mar;67(3):622-32. doi: 10.1093/jac/dkr524. Epub 2011 Dec 13.

15.

Penicillin susceptibility breakpoints for Streptococcus pneumoniae and their effect on susceptibility categorisation in Germany (1997-2013).

Imöhl M, Reinert RR, Tulkens PM, van der Linden M.

Eur J Clin Microbiol Infect Dis. 2014 Nov;33(11):2035-40. doi: 10.1007/s10096-014-2174-z. Epub 2014 Jun 15.

PMID:
24930041
16.

Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010).

Farrell DJ, Flamm RK, Jones RN, Sader HS.

Diagn Microbiol Infect Dis. 2013 Jan;75(1):86-8. doi: 10.1016/j.diagmicrobio.2012.06.005. Epub 2012 Nov 10.

PMID:
23146404
17.

Antimicrobial susceptibility of gram-negative and gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004-2010.

Balode A, Punda-Polić V, Dowzicky MJ.

Int J Antimicrob Agents. 2013 Jun;41(6):527-35. doi: 10.1016/j.ijantimicag.2013.02.022. Epub 2013 Apr 13.

PMID:
23590898
18.
19.

Evaluation by data mining techniques of fluconazole breakpoints established by the Clinical and Laboratory Standards Institute (CLSI) and comparison with those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST).

Cuesta I, Bielza C, Cuenca-Estrella M, Larrañaga P, Rodríguez-Tudela JL.

Antimicrob Agents Chemother. 2010 Apr;54(4):1541-6. doi: 10.1128/AAC.01688-09. Epub 2010 Feb 1.

20.

Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods.

Lu CL, Liu CY, Huang YT, Liao CH, Teng LJ, Turnidge JD, Hsueh PR.

Antimicrob Agents Chemother. 2011 Sep;55(9):4295-301. doi: 10.1128/AAC.00349-11. Epub 2011 Jun 13.

Items per page

Supplemental Content

Write to the Help Desk